SCHEMBL4378526

SCHEMBL4378526

COc1cccc(C(=O)C=CN2CCN(c3ccncc3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.51
ALDH1A1 P00352 7/20 0.50
CYP1A1 P04798 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP1B1 Q16678 2/20 0.50
MAOB P27338 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP3A4 P08684 1/20 0.49
MAPT P10636 6/20 0.49
LMNA P02545 3/20 0.49
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
RAB9A P51151 2/20 0.49
QSOX1 O00391 1/20 0.49
PKM P14618 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
GAA P10253 2/20 0.48
USP2 O75604 2/20 0.48
ALOX12 P18054 1/20 0.48
DRD4 P21917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377394 0.90 ALDH1A1 (0.51) ROCK2ALDH1A1CYP1A1CYP1A2CYP1B1
SCHEMBL4380518 0.81 ABCB1 (0.52) ALDH1A1CYP1A1CYP1A2CYP1B1CYP2D6
SCHEMBL4376233 0.78 TSHR (0.51) ALDH1A1CYP1A1CYP1A2CYP1B1CYP2D6
SCHEMBL4376027 0.77 NPC1 (0.53) ALDH1A1MAPTLMNANPC1SMN1; SMN2
SCHEMBL4375449 0.77 CYP3A4 (0.48) ALDH1A1CYP1A1CYP1A2CYP1B1CYP3A4
SCHEMBL7398283 0.76 MAPT (0.69) ROCK2ALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL18551819 0.74 ABCG2 (0.81) ALDH1A1CYP1A1CYP1A2CYP1B1MAOB
SCHEMBL4379062 0.74 NPC1 (0.45) ALDH1A1CYP1B1CYP3A4MAPTLMNA
SCHEMBL22771096 0.74 ABCG2 (0.74) ALDH1A1CYP1A1CYP1A2CYP1B1MAOB
SCHEMBL4378530 0.73 ACHE (0.64) ROCK2ALDH1A1CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 ROCK2 4139/4885ALDH1A1 1907/4885CYP1A1 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.